Aurum Publishes Paper on ABL-101 Technology

Aurum Publishes Paper on ABL-101 Technology

Aurum Biosciences Ltd, in collaboration with colleagues at the University of Glasgow and NHS Greater Glasgow and Clyde, have had a paper published in the journal Theranostics* (Impact factor 8.766). The paper describes work conducted at the university’s GEMRIC pre-clinical 7T scanner which investigated the use of Aurum’s ABL-101 perflurocarbon (previously known as Oxycyte) in an acute stroke model.

The paper investigated a new penumbral imaging technique (Lactate Spectroscopic Imaging or LSI) which utilised ABL-101 perflurocarbon and supplemental oxygen to provide metabolic information. Comparing LSI scans with and without supplemental oxygen can potentially allow identification of tissues under oxidative stress (anaerobic metabolism), which still has the potential for aerobic (oxidative) metabolism with increased oxygen delivery, therefore indicating the tissue as potentially salvageable. This new technology was investigated alongside Aurum’s T2* Oxygen Challenge imaging technology which aims to detects penumbral tissue using a modified BOLD imaging technique.

Both techniques were successful in detecting penumbral tissue in an animal model. Additionally Aurum collected data suggesting potential therapeutic benefit to animals that had been treated with ABL-101 technology.

Aurum aims to conduct early tests of this technology in stroke patients as part of its forthcoming Phase 2 clinical trial.


*Deuchar GA, Brennan D, Holmes WM, Shaw M, Macrae IM, Santosh C. Perfluorocarbon Enhanced Glasgow Oxygen Level Dependent (GOLD) Magnetic Resonance Metabolic Imaging Identifies the Penumbra Following Acute Ischemic Stroke. Theranostics 2018; 8(6):1706-1722. doi:10.7150/thno.21685. Available from